<DOC>
	<DOCNO>NCT01718808</DOCNO>
	<brief_summary>OBJECTIVE : The objective trial judge benefit obtain upfront cetuximab treatment deliver monotherapy part combination treatment capecitabine vulnerable elderly patient select V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) wild-type B-type Raf kinase ( BRAF ) wild-type metastatic colorectal cancer ( mCRC ) .</brief_summary>
	<brief_title>Cetuximab Elderly Patients With mCRC</brief_title>
	<detailed_description>Primary endpoint : If treatment arm number patient alive without progression 12 week 17 , arm consider promising , otherwise promise . Additionally , two-sided 95 % confidence interval difference Progression free survival ( PFS ) rate two arm calculate . Secondary endpoint patient characteristic : - Laboratory value may express absolute value ( continuous variable ) or/and grade ( ordinal categorical variable ) . - Generally categorical variable result summarize frequency percentage . For response rate 95 % Clopper-Pearson confidence interval calculate . - For adverse event , result summarize frequency percentage different grade among cycle well frequency percentages within-patient worst grade - For continuous variable result summarize descriptive statistic . - Time-to-event variable present Kaplan-Meier curve summarize median 95 % confidence interval . - All analysis do treatment arm .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patient give write informed consent trial specific treatment Histological proven diagnosis colorectal cancer , metastatic inoperable advance , amenable curative therapy Measurable disease , define least one lesion ( outside irradiate area ) measure least one dimension ≥ 10 mm ( ≥ 15 mm case lymph node ) accord RECIST v1.1 Tumour wildtype KRAS wildtype BRAF gene No previous systemic chemotherapy metastatic disease ( previous adjuvant chemotherapy allow complete &gt; 6 month randomization , previous rectal radiochemo therapy complete &gt; 1 month randomization ) WHO performance status 0 1 Age &gt; 75 year ; : age ≥ 70 year least one follow factor : Any functional dependence measure Instrumental Activities Daily Life ( IADL ) . Significant comorbidity accord Cumulative Illness Rating Scale geriatric patient ( CIRSG ; severe comorbidity &gt; grade 3 total score &gt; 5 qualifies ) Neutrophils ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L Bilirubin ≤ 2.0 x Upper Limit Normal ( ULN ) ( unless know GilbertMeulengracht syndrome ) , aspartate aminotransferase ( AST ) &lt; 2.5xULN Calculated creatinine clearance ≥ 30 ml/min . ( accord formula CockcroftGault ) Patient able swallow oral medication Baseline Quality Life form complete Documented suspect cerebral and/or leptomeningeal metastasis ( cerebral baseline imaging require asymptomatic patient ) Risk rapid deterioration due tumor symptom tumor complication Synchronous prior malignancy adequately treat nonmelanomatous skin cancer situ carcinoma cervix , malignancy unless disease free &gt; 2 year Prior antiEGFR ( Epidermal Growth Factor Receptor ) antibody therapy Severe uncontrolled cardiovascular disease ( e.g . acute coronary syndrome , cardiac failure NYHA ( New York Heart Association ) III IV , clinically relevant myopathy , history myocardial infarction within last 12 month , significant arrhythmia ) Concurrent severe uncontrolled medical illness ( judged investigator ) could impair ability patient participate trial ( e.g . uncontrolled infection , uncontrolled diabetes mellitus , active autoimmune disease ) Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Known hypersensitivity trial drug hypersensitivity component trial drug Definite contraindication use corticosteroid antihistamine premedication Lack physical integrity upper gastrointestinal tract malabsorption syndrome history inflammatory intestinal disease , disease could alter drug absorption Psychiatric disorder preclude understanding information trial related topic , give informed consent , fill QL form , interfere compliance oral drug intake Any concomitant drug contraindicate use trial drug accord Swissmedic approve product information Concurrent treatment experimental drug anticancer therapy and/or treatment clinical trial within 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>KRAS</keyword>
	<keyword>BRAF</keyword>
	<keyword>Wild-type Metastatic</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Phase II Trial</keyword>
	<keyword>Elderly Patients</keyword>
</DOC>